Austin Light Rail: Project could bring jobs to Austin
The Austin Light Rail project is on track to expand routes across the city
With this project, it could bring more jobs to the Austin area
Small business owners are getting the opportunity to network for the project
AUSTIN, Texas - As a $7 billion plan to bring light rail service to Austin moves forward, many local businesses and workers are hoping to help build it.
On Wednesday, the Austin Transit Partnership hosted an event for those businesses, and also gave an update on the project.
Timeline
"We want Austin to help us build this for Austin," said Austin Transit Partnership Executive Vice President for Design and Lindsay Wood.
The Austin Light Rail is on track. The 10-mile street-level railroad will stretch from 38th and Guadalupe Streets though the UT campus and into Downtown, then down Congress to Oltorf. Another branch will head east on Riverside Drive to SH 71. The project also allows for future extensions to the airport and the Crestview train station on North Lamar.
"We are actively seeking additional funding opportunities to be able to accelerate that extension," said Wood.
With construction set to start in 2027, the focus now turns to who will design and build the railroad and its 15 stations.
"Austin is looking at billions of dollars in construction," said Tina Cannon, a small business owner and CEO of the Austin LGBT Chamber of Commerce. "And now it's time for small businesses to get engaged and involved."
What they're saying
On Wednesday, the Austin Transit Partnership invited local companies who may want a piece of the three big contracts that will be up for grabs next year.
"So we're here today bringing on those potential industry partners that will need to help us get shovels in the ground," said Wood.
"Everything from nail and board type construction to engineering firms," said Cannon.
Austin-area small businesses sat alongside big construction outfits for networking and training workshops.
"It's all about relationships," said Helen Callier, founder of Permit Us Now. "To, number one, see folks we may already know and have some conversations. And number two, see folks we may not have met before in the industry to be able to start those conversations."
"It's a chance for small businesses to have a say now. So then when it comes time to actually bid on the process, it's a much smoother process," said Cannon.
In the meantime, the Austin Transit Partnership is working on getting federal funding for the $7.1 billion project, which is expected to bring thousands of local jobs.
"All boats rise together," said Callier. "So for the small businesses, we play a critical role in the economy in the local area, for Austin and, of course, the surrounding communities. And it makes a difference."
Why you should care
If you're a business owner who would like to get involved but weren't able to make it to Wednesday's event, click here.
The Source
Information from interviews conducted by FOX 7 Austin's John Krinjak
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
15 minutes ago
- Business Wire
Dynamic Wealth Advisors Named No. 1 in Arizona as Part of ‘50 Growers Across America'
PHOENIX--(BUSINESS WIRE)--Dynamic Wealth Advisors, the Registered Investment Advisor (RIA) arm of Dynamic Advisor Solutions, a preeminent partner to wealth advisors, was recognized by Citywire RIA as one of the 50 Growers Across America 2025 in Arizona, spotlighting its top position as the state's fastest-growing RIA. This recognition comes as Dynamic continues its strategic expansion—now overseeing more than $6 billion in assets under administration (AUA)—by investing in modern infrastructure, expanding its offerings and enhancing advisor support systems. This recognition comes as Dynamic continues its strategic expansion—now overseeing more than $6 billion in assets under administration (AUA)—by investing in modern infrastructure, expanding its offerings and enhancing advisor support systems. This includes: Advancing technology infrastructure, integrating AI-driven tools, real-time risk intelligence and sophisticated financial planning functionality, allowing advisors to operate with greater efficiency and serve clients more effectively. Expanding Asset Management, providing advisors with robust investor support and a wide-ranging, customizable suite of strategies that adapt to evolving client needs and market unpredictability. Growing people-first approach, welcoming new hires across Business Development, Onboarding and Advisor Support teams to improve the advisor journey — from recruitment to retention and practice management. Deepening and growing strategic partnerships, strengthening the Dynamic ecosystem and giving advisors access to more resources, collaborative opportunities and cost savings. Launching a redesigned website, showcasing Dynamic network advisors and the firm's flexibility in offering multiple affiliation models from which to choose, empowering advisors to tailor their career paths as well as client service models. 'Being named the top grower in Arizona is a testament to the advisors who choose to partner with us and our teams that support their growth,' said Jim Cannon, Dynamic founder and CEO. 'Their development and care for clients drive everything we do. Our mission is to walk alongside them, investing in the technology, people and support systems that help them reach their business goals and deliver exceptional outcomes for their clients." Cannon added, 'We continue to direct our efforts toward enhancing the advisor experience, ensuring they have the right tools, support and opportunities to do their best work and achieve lasting growth.' In an Aug. 11, 2025, announcement from FINTRX, the exclusive data provider in this year's edition of Citywire RIA's '50 Growers Across America' report, Citywire Editor Ian Wenik explained, 'Firms are included in the list based purely on data. There's no submission process, no subjective evaluation from a panel, and inclusion doesn't imply endorsement—it simply means these are some of the fastest-growing firms in their respective states.' About Dynamic Advisor Solutions dba Dynamic Wealth Advisors Dynamic is a steadfast partner to independent wealth advisors at every stage of their business journey — whether transitioning to independence, scaling an established practice, planning for succession or seeking turnkey asset management platform (TAMP) services. With multiple affiliation models from which to choose, Dynamic delivers a bespoke business solution that combines the people, resources and technology needed to help advisors grow their firms and provide exceptional client experiences. Dynamic partners with more than 80 wealth advisory practices across the U.S., serving over 5,800 clients and administering more than $6 billion in assets. Learn more at About Citywire RIA's '50 Growers Across America' Citywire RIA's '2025 50 Growers Across America' report spotlights the fastest-growing independent RIAs in each state, using a 'growth-factor' approach that focuses on assets under management (AUM) growth, absolute AUM increase and employee headcount expansion. With FINTRX as the exclusive data provider for this year's edition, the ranking is based entirely on objective data with no submission fees required. Investment advisory services are offered through Dynamic Advisor Solutions, LLC, dba Dynamic Wealth Advisors, an SEC registered investment advisor.
Yahoo
3 hours ago
- Yahoo
Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
AUSTIN, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the Company to initiate its Phase 2 'RENEW' clinical trial of LTI-03, the Company's lead drug candidate for idiopathic pulmonary fibrosis (IPF). IPF is a serious, progressive lung disease that affects hundreds of thousands of people worldwide. It scars the lungs, leaving patients short of breath and with limited treatment options. Median survival after diagnosis is just 3–5 years. Rein's LTI-03 is a first-in-class therapy that is designed to directly target fibrosis while also protecting the lung's ability to regenerate healthy tissue. If successful, it could represent a major breakthrough in how pulmonary fibrosis is treated. Brian Windsor, Chief Executive Officer of Rein Therapeutics, commented, 'This MHRA approval marks an important milestone not only for Rein, but also for patients living with IPF. We are now working towards patient recruitment in the U.K., advancing LTI-03 into the next stage of development. Our approach is designed not only to slow disease progression, but also to preserve, and potentially restore, the lung cells that are critical to everyday breathing and quality of life. We believe LTI-03 has the potential to transform outcomes for patients while also creating substantial value for our shareholders.' Next Steps The RENEW trial is expected to enroll up to 120 patients worldwide, evaluating two dose groups of LTI-03 against a placebo. The primary objective of the trial is to assess safety and tolerability over 24 weeks of treatment. Secondary endpoints will include measures of lung function and imaging-based assessments of fibrosis progression. Rein is actively working with clinical sites in the UK to begin patient recruitment soon, with initial data expected in 2026. About Rein Therapeutics Rein Therapeutics is a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and fibrosis indications. Rein's lead product candidate, LTI-03, is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. LTI-03 has received Orphan Drug Designation in the U.S. and is in clinical development. Rein's second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the U.S. and E.U. and Fast Track Designation in the U.S. Forward-Looking Statements This press release may contain forward-looking statements of Rein Therapeutics, Inc. ("Rein", the "Company", "we", "our" or "us") within the meaning of the Private Securities Litigation Reform Act of 1995, including statements with respect to expectations for the Company's LTI-03 product candidate, the planned UK Phase 2 clinical trial of LTI-03 and the initial data readouts from the planned UK clinical trial. We use words such as "anticipate," "believe," "estimate," "expect," "hope," "intend," "may," "plan," "predict," "project," "target," "potential," "would," "can," "could," "should," "continue," and other words and terms of similar meaning to help identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including (i) the risk that the Company may not be able to successfully undertake the planned UK Phase 2 clinical trial of LTI-03, (ii) success in early phases of pre-clinical and clinicals trials do not ensure later clinical trials will be successful; (iii) the risk that the Company may not be able to obtain additional working capital with which to initiate and complete planned UK clinical trial, (iv) the risk that the Company may not be able to announce initial data readouts from the planned UK clinical trial in 2026 or, if it is able to do so, that the data may not be favorable and (v) those other risks disclosed in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2024, which is on file with the United States Securities and Exchange Commission (the "SEC") and in subsequent filings that the Company files with the SEC. These forward-looking statements should not be relied upon as representing the Company's view as of any date after the date of this press release, and we expressly disclaim any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Rein Investor Relations & Media Contact: Investor Relations IR@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
Natural Grocers® Announces Closure of Austin, Texas - Arbor Walk Store on Oct. 2, 2025
LAKEWOOD, Colo., Aug. 19, 2025 /PRNewswire/ -- Natural Grocers® will close its Austin – Arbor Walk location, at 10515 N. MoPac Expressway, on Oct. 2, 2025. Storewide closing sales will begin on Tuesday, Sept. 2, with 25% off all items, including body care and beauty products, dairy, meat, produce, supplements and more. All sales will be final. The Arbor Walk store has served customers since 2010 as the company's second Austin location. It is one of four Natural Grocers stores in the Austin region and one of 25 across Texas. The closure follows unsuccessful lease renewal negotiations, but all other Austin-area and Texas locations remain open to serve customers. "Austin has always held a special place in our story," said Kemper Isely, Natural Grocers' co-president. "From the day we opened our first Austin-area store in 2009, we have felt embraced by a community that values health, individuality and creativity—values that resonate deeply with who we are as a company. While we are disappointed to close our Arbor Walk location due to an unresolved lease renewal, this decision allows us to focus on strengthening our presence across the Austin area and beyond. We remain deeply committed to serving our customers here and are grateful for the support this store has received over the past 15 years." The Company is working closely with each of its valued good4uSM Crew members through the closure to support them during the transition. This includes identifying potential transfer opportunities at nearby stores or offering a transition package, including severance and continuation of health benefits. SHOPPING OPTIONS NEARBY Following Arbor Walk store's closure, customers can visit one of Natural Grocers' nearby locations: Austin Area – Cedar Park Austin Area – Georgetown Austin Area – North Lamar Blvd Temple Waco Learn more about Natural Grocers at Please direct media inquiries to kmacarelli@ ABOUT NATURAL GROCERS BY VITAMIN COTTAGEFounded in 1955, Natural Grocers by Vitamin Cottage, Inc. (NYSE: NGVC) is an expanding specialty retailer of natural and organic groceries, body care products, and dietary supplements. The grocery products sold by Natural Grocers must meet strict quality guidelines and may not contain artificial flavors, preservatives, or sweeteners (as defined by its standards), synthetic colors, or partially hydrogenated or hydrogenated oils. The Company sells only USDA-certified organic produce and exclusively pasture-raised, non-confinement dairy products, and free-range eggs. Natural Grocers' flexible smaller-store format allows it to offer affordable prices in a shopper-friendly, clean, and convenient retail environment. The Company also provides extensive free science-based Nutrition Education programs to help customers and Crew make informed health and nutrition choices. Natural Grocers is committed to its Five Founding Principles—including its "Commitment to Community" and "Commitment to Crew". In fiscal year 2024, the Company invested more than $15 million in incremental compensation and discretionary payments for Crew. Headquartered in the Union Square neighborhood of Lakewood, CO, Natural Grocers has 169 stores in 21 states. Visit for more information and store locations. View original content to download multimedia: SOURCE Natural Grocers by Vitamin Cottage, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
